Left Ventricular Hypertrophy Among Chronic Kidney Disease Patients in Assiut University Hospital

Chronic Kidney Diseases Clinical Trial

Official title:

Left Ventricular Hypertrophy Among Chronic Kidney Disease Patients in Assiut University Hospital

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05002010
• Other study ID #: LVH in CKD
• Status: Not yet recruiting
• Start date: February 2022
• Est. completion date: December 2022

Study information

• Verified date: February 2022
• Source: Assiut University
• Contact: Heba Mohammed
• Phone: 01553466968
• Email: Hebamohammed180[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Assess the prevalence and features of left ventricular hypertrophy in patients with chronic kidney disease (CKD) taking into account gender differences and stage of CKD.

To detect factors those predict LVH in CKD.

*to assess the right ventricle dysfunction in CKD .

Description:

The number of patients with chronic kidney disease (CKD) is growing worldwide, while patients with impaired renal function are at high or very high risk for developing cardiovascular disease (CVD). Mortality due to CVD in patients with CKD is 1020 times higher than that in the general population, and the likelihood of developing cardiovascular complications (CVC) is several times higher than the risk of end-stage CKD{1} In CKD cardiovascular disease abnormalities are due to volume overload, hypertension, endothelia dysfunction, inflammation, uremic pericarditis cardiomyopathy, anemia, dyslipidemia and oxidativel stress{2} Left ventricular hypertrophy (LVH) is a key feature that allows you to get an accurate picture of systolic-diastolic lesions of the left heart in patients with CKD and therefore is one of the most important factors in the development of adverse CVC LVH is initially formed as an adaptive process aimed at maintaining normal heart function under conditions of myocardial overload by pressure or volume, but then acquires the character of pathological adaptation, becoming the structural basis of heart failure, myocardial ischemia and cardiac arrhythmias {3}. It was shown that the probability of LVH increases already with a moderate decrease in eGFR and increases further as CKD progresses, reaching a maximum in the terminal stage [4].

. in CKD LVH is associated with increased mortality and the risk of adverse outcomes, especially at the terminal stage of CKD{5-6}

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: December 2022
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients with chronic renal disease (CKD) aged between 16 and 65 years will be included.

2- CKD are diagnosed based on criteria proposed by KDIGO (Kidney Disease: Improving Global Outcomes) in 2002

Exclusion Criteria:

• Patients with structural heart disease (congenital or valvular heart disease). Patients with primary hypertension. Patients with obstructive or restrictive lung disease.

Related Conditions & MeSH terms

• Chronic Kidney Diseases
• Hypertrophy
• Hypertrophy, Left Ventricular
• Kidney Diseases
• Left Ventricular Hypertrophy
• Renal Insufficiency, Chronic

Intervention

Device:
• Echo
Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (1)

Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr Cardiol Rev. 2019;15(1):55-63. doi: 10.2174/1573403X14666180711124825. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detecting the prevalence of LVH in CKD.	The types of LVH in different stages of CKD. Risk factors of LVH in different stages of CKD	through study completion, an average of 1 year".
Secondary	The types of LVH in different stages of CKD. Risk factors of LVH in different stages of CKD		through study completion, an average of 1 year".